Haitong Invests in Orig3n, a Boston Genetics/Regenerative Medicine Company

Haitong International of Hong Kong led the first close of a Series B round in Orig3n, a Boston genetics and regenerative medicine company. The size of the round was not disclosed, but Orig3n has raised $50 million since it was founded in 2014. Orig3n offers personalized genetics tests, and it is developing an allogenic cell bank, mostly from crowdsourced samples, that it will use to advance regenerative treatments for disease. The company expects its partner to discover regenerative treatments for cystic fibrosis, Parkinson's disease and frontotemporal dementia. More details....

Share this with colleagues:

More From BioPortfolio on "Haitong Invests in Orig3n, a Boston Genetics/Regenerative Medicine Company"